In pancreatic cancer cells, MAP4K3 knockdown cells failed to phosphorylate PKCθ, and inhibition of PKCθ activity suppressed insulin-like growth factor-1-mediated cell growth and viability, indicating that the MAP4K3/PKCθ axis may be a therapeutic target for pancreatic cancer [261]. This evidence concerns the gene PRRT2 and familial pancreatic carcinoma.